Presentation: 4B04

Quantitative imaging cytometry is emerging as a powerful bioassay tool for cellular high content screening of lead compounds in the pharmaceutical industry. In the core flow cytometry laboratory at Amgen, technological advances allow for quantitative imaging in therapeutic area research and development, addressing issues such as pathway signaling, toxicology and biomarkers. Here we discuss three high content platforms, used individually and in conjunction with each other: laser-scanning cytometry, imaging flow cytometry and confocal microscopy. Traditional cellular assays such as cell cycle/proliferation, drug induced phospholipidosis and micronucleation, evaluation of protein secretion, and others, can be enhanced using imaging cytometry. Correlation of images with cytometric data allows for a more accurate screening in the drug discovery process. Measurement of otherwise 'invisible' fluorescent events such as sub-cellular localization, makes qualitative images a thing of the past.

Close Window X